Gastroenterology
Volume 138, Issue 3 , Pages 886-895.e1 , March 2010

Efficacy of Linaclotide for Patients With Chronic Constipation

  • Anthony J. Lembo

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (BIDMC)
    • ,
  • Caroline B. Kurtz

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • James E. MacDougall

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • B.J. Lavins

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • Mark G. Currie

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • Donald A. Fitch

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • Brenda I. Jeglinski

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • ,
  • Jeffrey M. Johnston

      Affiliations

    • Ironwood Pharmaceuticals Inc., Cambridge, Massachusetts
    • Corresponding Author InformationReprint requests Address requests for reprints to: Jeffrey M. Johnston, Ironwood Pharmaceuticals, Inc., 320 Bent Street, Cambridge, Massachusetts 02141

Received 19 August 2009 ,Accepted 8 December 2009.

References 

  1. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol. 1999;94:3530–3540
  2. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–759
  3. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–1368
  4. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96:3130–3137
  5. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26:227–236
  6. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608
  7. Talley NJ, Lasch KL, Baum CL. A gap in our understanding: chronic constipation and its comorbid conditions. Clin Gastroenterol Hepatol. 2009;7:9–19
  8. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 2008;20(Suppl 1):121–129
  9. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237–248
  10. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006;19:43–49
  11. Tack J, Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009;7:502–508quiz 496
  12. Schiller LR, Johnson DA. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. Am J Gastroenterol. 2008;103:815–819
  13. Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177
  14. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361
  15. Forte LR. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther. 2004;104:137–162
  16. Currie MG, Fok KF, Kato J, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1992;89:947–951
  17. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761–768
  18. Bueno L, Beaufraud C, Mahajan-Miklos S, et al. Antinocicetive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain. Am J Gastroenterol. 2004;99(Suppl 2):A283
  19. Ustinova E, Bryant A, Reza T, et al. Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental pain. Am J Gastroenterol. 2008;103(Suppl 1):S187
  20. Kurtz CB, Fitch D, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacoldynamics in healthy subjects. Gastroenterology. 2006;130(Suppl 2):A26
  21. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol. 2009;104:125–132
  22. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):II43–II47
  23. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491
  24. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560
  25. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–924
  26. Marquis P, De La Loge C, Dubois D, et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40:540–551
  27. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354

 Conflicts of interest The authors disclose the following: Jeffrey Johnston, Caroline Kurtz, James MacDougall, Bernard Lavins, Donald Fitch, Brenda Jeglinski, and Mark Currie are employees of Ironwood Pharmaceuticals. Anthony Lembo is a consultant to Ironwood Pharmaceuticals.

 Funding This study was funded by Ironwood Pharmaceuticals.

PII: S0016-5085(09)02247-1

doi: 10.1053/j.gastro.2009.12.050

Gastroenterology
Volume 138, Issue 3 , Pages 886-895.e1 , March 2010

Article Tools

* Image Usage & Resolution